Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Researchers crack a key driver of deadly breast cancer spread. Australian scientists have identified a molecule called miR-342 that acts as a master regulator in triple-negative breast cancer (TNBC), the most aggressive and hard-to-treat subtype. When miR-342 levels drop, cancer spreads more aggressively — but restoring it, or using the existing drug palbociclib, dramatically reduced metastatic growth in lab models.
Australian scientists from Adelaide University and the Olivia Newton-John Cancer Research Institute have pinpointed a molecular switch — a naturally occurring molecule called miR-342 — that controls the spread of triple-negative breast cancer (TNBC). Published in EMBO Molecular Medicine, the study found that patients with low miR-342 levels and high activity of the cancer-driving E2F pathway were significantly more likely to develop metastatic disease.
When miR-342 levels fall, the E2F pathway becomes overactive, allowing dormant cancer cells already circulating in the body to grow into dangerous secondary tumors in organs like the lungs and bones. Restoring miR-342 in pre-clinical models markedly reduced this spread — and the already-approved CDK4/6 inhibitor palbociclib showed strong effectiveness in suppressing metastatic tumor growth in low-miR-342 models.
Key Takeaways:
Why it matters: TNBC accounts for 10–15% of breast cancer diagnoses but causes a disproportionate share of deaths due to its aggressive nature and limited treatment options. This discovery opens the door to repurposing an existing, approved therapy for a carefully selected patient subset — a potentially faster path to clinical impact.
